Document:

Exhibit 10.6

 

EXECUTION

 

AMENDMENT

 

Whereas, Addex Pharma SA (“Addex”) and Indivior UK Limited (Co. No. 7183451) (“Indivior”) entered into an agreement to perform research on GABA B PAM on January 2, 2018 (hereinafter, Agreement);

 

Whereas, Addex has conducted a funded research activity based on an agreed Research Plan over the period 1 May 2018 to 30 April 2020 and Indivior has paid $5.6 million in research funding;

 

Whereas, on completion of the Research Term as originally envisaged the Parties agreed that no Development Compounds had been identified but the Parties desire to continue the research with a view to identifying Development Compounds.

 

Now Therefore, in consideration of the premises and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged Addex and Indivior hereby agree as follows:

 

1.             Definitions. The definitions from the Agreement of January 2, 2018 between Addex and Indivior shall be used in this Amendment and are incorporated herein by reference.

 

2.             Effective Date. The Effective Date of this Amendment shall be 1 August 2020.

 

3.             Initial Research Term Extension. With reference to Article 3.3 of the Agreement, subject to the provisions of this Amendment Agreement, the Parties agree to extend the Research Term until 30 June 2021:

 

a.            As a contribution to the costs of the research between the Effective Date of this Amendment and 31 October 2020, as detailed in the Research Plan in Appendix 1, Indivior shall pay to Addex the sum of one million five hundred thousand dollars ($1,500,000) within [***] of the signature of this amendment. The provisions of Section 6.9 of the Agreement shall apply to such payment. Addex shall provide an invoice for the payment due.

 

b.            All Compounds that are identified as “Peripheral Compounds” (whether prior to 31 October 2020 or during any work subsequently conducted in relation to the Research Plan shall become Addex Retained Compounds where “Peripheral Compounds shall be any Compounds that show [***].

 

c.             On or before [***], Addex shall deliver to Indivior a report that sets out all of the Compounds identified in the course of undertaking the Research Plan up to [***] and identifying those which Addex believes are suitable for further development.

 

d.         Prior to [***] the Parties shall mutually agree in writing a further revision of the Research Plan and associated budget, which will be payable by Indivior. The draft Research Plan for clinical candidate selection phase which is

 

 

expected to take place from [***] to [***] is detailed in  Appendix 2.

 

e.          As a contribution to the costs of the research between [***] and [***], as detailed in the Draft Research Plan in Appendix 2, Indivior shall pay to Addex a sum of [***] within [***] days of agreement of the Research Plan. This payment will be creditable against the total agreed budget for this phase. The provisions of Section 6.9 of the Agreement shall apply to such payments. Addex shall invoice Indivior for all payments due.

 

f.           In the event that the costs of undertaking the Research Plan between 1 November 2020 and 30 April 2021, exceed [***] the Parties shall discuss the funding of that part of the Research Plan that exceeds such cost and Addex shall not be in breach of the Agreement if it elects not to undertake any part of the Research Plan that would result in the costs incurred by it in the Research Plan exceeding [***]. 

 

g.          In the event the Parties cannot agree an amendment to the Research Plan for the period from [***] to [***] or the funding of the Research Plan during such period then Addex shall have no obligation to undertake any work in respect of the discovery, research or development of Compounds during such period.

 

h.         In the event that:

 

i.             the Parties cannot agree a further revision to the Research Plan prior to [***] the Agreement shall terminate in its entirety on [***] and the provisions of Section 10.2 of the Agreement shall not apply;or

 

ii.            the parties have agreed a further revision to the Research Plan prior to [***] but Indivior does not select any Licensed Compounds on or before [***] the Agreement shall terminate in its entirety on [***] and the provisions of Section 10.2 of the Agreement shall not apply.

 

4.    Amendment of Definition of Reserved Indications. As of the Effective Date of this Amendment, the definition of Reserved Indications in Section 1.73 of the Agreement shall be deleted in its entirety and replaced by the following:

 

1.73                     “Reserved Indications” means the following Indications:

 

(a)                                 Polyneuropathies and other disorders of the peripheral nervous system (G60 to G64) including but not limited to Charcot Marie Tooth (G60);

 

(b)                                 [***] including but not limited to [***];

 

(c)                                  [***] including but not limited to [***];

 

 

(d)           [***];

 

(e)           [***] including but not limited to [***] such as [***];

 

(f)            [***] including but not limited to [***];

 

(g)           [***] including but not limited to [***]; and

 

(h)           [***] including but not limited to [***].

 

5.            Potential Addition of a Shared Indication. In the event that Indivior has not dosed a patient in a clinical study directed to the treatment of  [***]   on or before [***], then, with effect from [***], the definition of Shared Indications in Section 1.78 of the Agreement shall be deleted in its entirety and replaced by the following:

 

1.78  “Shared Indications” means the following Indications: [***] and [***];

 

6.            Amendment of Section 2.8 of the Agreement. As of the Effective Date of this Amendment, Section 2.8 of the Agreement shall be deleted in its entirety and replaced by the following:

 

2.8  Field Restrictions. During the Term, Indivior shall not, directly or indirectly (including through sublicensees and Affiliates), file for any IND or conduct clinical trials in humans with respect to Compounds, Licensed Compounds or Products outside of the Field and Addex shall not, directly or indirectly (including through licensees and Affiliates), file for any IND or conduct clinical trials in humans (except as expressly provided in this Agreement) with respect to, Addex Retained Compounds or Addex Products outside of the Reserved Indications.

 

7.            Remainder of Agreement. The provisions of Section 14 of the Agreement shall apply to this First Amendment and, save as specifically amended hereby, the Agreement of January 2, 2018 will remain in full force and effect.

 

 

IN WITNESS WHEREOF, ADDEX and Indivior have caused this instrument to be executed in duplicate by their respective duly authorized officers.

 

	
 
    	
Indivior   UK Limited.
    
	
 
    	
Date:
    	
10/30/2020
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ Ryan Preblick
    
	
 
    	
Name:
    	
Ryan Preblick
    
	
 
    	
Title:
    	
Interim CFO
    
	
 
    	
 
    	
 
    
	
 
    	
Addex Pharma SA
    
	
 
    	
Date:
    	
10/30/2020
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/ Tim Dyer
    
	
 
    	
Name:
    	
Tim Dyer
    
	
 
    	
Title:
    	
Chief Executive OfficerEX-10.1

 Exhibit 10.1 

BENITEC BIOPHARMA INC. 

2020 EQUITY AND INCENTIVE COMPENSATION PLAN 

1.    Purpose. The purpose of this Plan is to permit award grants to
non-employee Directors, officers and other employees of the Company and its Subsidiaries, and certain consultants to the Company and its Subsidiaries, and to provide to such persons incentives and rewards for
service and/or performance. 
 2.    Definitions. As used in this Plan: 

(a)    “Appreciation Right” means a right granted pursuant to
Section 5 of this Plan. 
 (b)    “Base Price” means the price
to be used as the basis for determining the Spread upon the exercise of an Appreciation Right. 

(c)    “Board” means the Board of Directors of the Company. 

(d)    “Business Combination” has the meaning set forth in
Section 12(c) of this Plan. 
 (e)    “Cash Incentive Award”
means a cash award granted pursuant to Section 8 of this Plan. 

(f)    “Change in Control” has the meaning set forth in
Section 12 of this Plan. 
 (g)    “Code” means the Internal
Revenue Code of 1986, as amended from time to time, and the regulations thereunder, as such law and regulations may be amended from time to time. 

(h)    “Committee” means the Compensation Committee of the Board (or its successor(s)), or any other
committee of the Board designated by the Board to administer this Plan pursuant to Section 10 of this Plan. 

(i)    “Common Stock” means the common stock, par value $0.0001 per share, of the Company or any security into
which such common stock may be changed by reason of any transaction or event of the type referred to in Section 11 of this Plan. 

(j)    “Company” means Benitec Biopharma Inc., a Delaware corporation, and its successors. 

(k)    “Date of Grant” means the date provided for by the Committee on which a grant of Option Rights,
Appreciation Rights, Performance Shares, Performance Units, Cash Incentive Awards, or other awards contemplated by Section 9 of this Plan, or a grant or sale of Restricted Stock, Restricted Stock Units,
or other awards contemplated by Section 9 of this Plan, will become effective (which date will not be earlier than the date on which the Committee takes action with respect thereto). 

(l)    “Director” means a member of the Board. 

(m)    “Effective Date” means the date this Plan is approved by the Stockholders. 

(n)    “Evidence of Award” means an agreement, certificate, resolution or other type or form of writing or other
evidence approved by the Committee that sets forth the terms and conditions of the awards granted under this Plan. An Evidence of Award may be in an electronic medium, may be limited to notation on the books and records of the Company and, unless
otherwise determined by the Committee, need not be signed by a representative of the Company or a Participant. 

(o)    “Exchange Act” means the Securities Exchange Act of 1934, as amended from time to time, and the rules and
regulations thereunder, as such law, rules and regulations may be amended from time to time. 
 (p)    “Incentive
Stock Option” means an Option Right that is intended to qualify as an “incentive stock option” under Section 422 of the Code or any successor provision. 

 (q)    “Incumbent Board” has the meaning set forth in
Section 12(b) of this Plan. 
 (r)    “Management Objectives”
means the measurable performance objective or objectives established pursuant to this Plan for Participants who have received grants of Performance Shares, Performance Units or Cash Incentive Awards or, when so determined by the Committee, Option
Rights, Appreciation Rights, Restricted Stock, Restricted Stock Units, dividend equivalents or other awards pursuant to this Plan. If the Committee determines that a change in the business, operations, corporate structure or capital structure of the
Company, or the manner in which it conducts its business, or other events or circumstances render the Management Objectives unsuitable, the Committee may in its discretion modify such Management Objectives or the goals or actual levels of
achievement regarding the Management Objectives, in whole or in part, as the Committee deems appropriate and equitable. 

(s)    “Market Value per Share” means, as of any particular date, the closing price of a share of Common Stock
as reported for that date on the Nasdaq Stock Market or, if the Common Stock is not then listed on the Nasdaq Stock Market, on any other national securities exchange on which the Common Stock is listed, or if there are no sales on such date, on the
next preceding trading day during which a sale occurred. If there is no regular public trading market for the Common Stock, then the Market Value per Share shall be the fair market value as determined in good faith by the Committee. The Committee is
authorized to adopt another fair market value pricing method provided such method is stated in the applicable Evidence of Award and is in compliance with the fair market value pricing rules set forth in Section 409A of the Code. 

(t)    “Optionee” means the optionee named in an Evidence of Award evidencing an outstanding Option Right. 

(u)    “Option Price” means the purchase price payable on exercise of an Option Right. 

(v)    “Option Right” means the right to purchase Common Stock upon exercise of an award granted pursuant to
Section 4 of this Plan. 
 (w)    “Outstanding Company Common
Stock” has the meaning set forth in Section 12(a) of this Plan. 

(x)    “Outstanding Company Voting Securities” has the meaning set forth in
Section 12(a) of this Plan. 
 (y)    “Participant” means a
person who is selected by the Committee to receive benefits under this Plan and who is at the time (i) a non-employee Director, (ii) an officer or other employee of the Company or any Subsidiary,
including a person who has agreed to commence serving in such capacity within 90 days of the Date of Grant, or (iii) a person, including a consultant, who provides services to the Company or any Subsidiary that are equivalent to those typically
provided by an employee (provided that such person satisfies the Form S-8 definition of an “employee”). 

(z)    “Performance Period” means, in respect of a Cash Incentive Award, Performance Share or Performance Unit,
a period of time established pursuant to Section 8 of this Plan within which the Management Objectives relating to such Cash Incentive Award, Performance Share or Performance Unit are to be achieved.

 (aa)    “Performance Share” means a bookkeeping entry that records the equivalent of one share of Common
Stock awarded pursuant to Section 8 of this Plan. 

(bb)    “Performance Unit” means a bookkeeping entry awarded pursuant to
Section 8 of this Plan that records a unit equivalent to $1.00 or such other value as is determined by the Committee. 

(cc)    “Person” has the meaning set forth in Section 12(a) of
this Plan. 
 (dd)    “Plan” means this Benitec Biopharma Inc. 2020 Equity and Incentive Compensation Plan, as
may be amended or amended and restated from time to time. 

  
 2 

 (ee)    “Restricted Stock” means Common Stock granted or sold
pursuant to Section 6 of this Plan as to which neither the substantial risk of forfeiture nor the prohibition on transfers has expired. 

(ff)    “Restricted Stock Units” means an award made pursuant to
Section 7 of this Plan of the right to receive Common Stock, cash or a combination thereof at the end of the applicable Restriction Period. 

(gg)    “Restriction Period” means the period of time during which Restricted Stock Units are subject to
restrictions, as provided in Section 7 of this Plan. 

(hh)    “Spread” means the excess of the Market Value per Share on the date when an Appreciation Right is
exercised over the Base Price provided for with respect to the Appreciation Right. 
 (ii)    “Stockholder”
means an individual or entity that owns one or more shares of Common Stock. 
 (jj)    “Subsidiary” means a
corporation, company or other entity (i) more than 50% of whose outstanding shares or securities (representing the right to vote for the election of directors or other managing authority) are, or (ii) which does not have outstanding shares
or securities (as may be the case in a partnership, joint venture, limited liability company, unincorporated association or other similar entity), but more than 50% of whose ownership interest representing the right generally to make decisions for
such other entity is, now or hereafter, owned or controlled, directly or indirectly, by the Company; provided, however, that for purposes of determining whether any person may be a Participant for purposes of any grant of Incentive
Stock Options, “Subsidiary” means any corporation in which the Company at the time owns or controls, directly or indirectly, more than 50% of the total combined Voting Power represented by all classes of stock issued by such corporation.

 (kk)    “Voting Power” means, at any time, the combined voting power of the then-outstanding securities
entitled to vote generally in the election of Directors in the case of the Company or members of the board of directors or similar body in the case of another entity. 

3.    Shares Available Under this Plan. 
  

	 	(a)	 Maximum Shares Available Under this Plan. 

 

	 	(i)	 Subject to adjustment as provided in Section 11 of this Plan and
the share counting rules set forth in Section 3(b) of this Plan, the number of shares of Common Stock available under this Plan for awards of (A) Option Rights or Appreciation Rights,
(B) Restricted Stock, (C) Restricted Stock Units, (D) Performance Shares or Performance Units, (E) awards contemplated by Section 9 of this Plan, or (F) dividend equivalents
paid with respect to awards made under this Plan will not exceed in the aggregate (x) 700,000 shares of Common Stock, plus (y) the Common Stock that is subject to awards granted under this Plan that is added (or added back, as applicable) to
the aggregate number of shares of Common Stock available under this Section 3(a)(i) pursuant to the share counting rules of this Plan. Such shares may be shares of original issuance or treasury shares
or a combination of the foregoing. 

  

	 	(ii)	 Subject to the share counting rules set forth in Section 3(b) of
this Plan, the aggregate number of shares of Common Stock available under Section 3(a)(i) of this Plan will be reduced by one share of Common Stock for every one share of Common Stock subject to an
award granted under this Plan. 

 (b)    Share Counting Rules. 

 

	 	(i)	 Except as provided in Section 22 of this Plan, if any award
granted under this Plan (in whole or in part) is cancelled or forfeited, expires, is settled for cash, or is unearned, the Common Stock subject to such award will, to the extent of such cancellation, forfeiture, expiration, cash settlement, or
unearned amount, again be available under Section 3(a)(i) above. 

  
 3 

	 	(ii)	 Notwithstanding anything to the contrary contained in this Plan: (A) Common Stock withheld by the Company,
tendered or otherwise used in payment of the Option Price of an Option Right will not be added (or added back, as applicable) to the aggregate number of shares of Common Stock available under
Section 3(a)(i) of this Plan; (B) Common Stock withheld by the Company, tendered or otherwise used to satisfy tax withholding will not be added (or added back, as applicable) to the aggregate
number of shares of Common Stock available under Section 3(a)(i) of this Plan; (C) Common Stock subject to a share-settled Appreciation Right that is not actually issued in connection with the
settlement of such Appreciation Right on the exercise thereof will not be added back to the aggregate number of shares of Common Stock available under Section 3(a)(i) of this Plan; and (D) Common
Stock reacquired by the Company on the open market or otherwise using cash proceeds from the exercise of Option Rights will not be added (or added back, as applicable) to the aggregate number of Common Stock available under
Section 3(a)(i) of this Plan. 

  

	 	(iii)	 If, under this Plan, a Participant has elected to give up the right to receive compensation in exchange for
Common Stock based on fair market value, such Common Stock will not count against the aggregate limit under Section 3(a)(i) of this Plan. 

(c)    Limit on Incentive Stock Options. Notwithstanding anything to the contrary contained in this Plan, and
subject to adjustment as provided in Section 11 of this Plan, the aggregate number of shares of Common Stock actually issued or transferred by the Company upon the exercise of Incentive Stock Options
will not exceed 700,000 shares of Common Stock. 
 (d)    Non-Employee
Director Compensation Limit. Notwithstanding anything to the contrary contained in this Plan, in no event will any non-employee Director in any one calendar year be granted compensation for such service
having an aggregate maximum value (measured at the Date of Grant as applicable, and calculating the value of any awards based on the grant date fair value for financial reporting purposes) in excess of $500,000. 

4.    Option Rights. The Committee may, from time to time and upon such terms and conditions as it may determine,
authorize the granting to Participants of Option Rights. Each such grant may utilize any or all of the authorizations, and will be subject to all of the requirements, contained in the following provisions: 

(a)    Each grant will specify the number of shares of Common Stock to which it pertains subject to the limitations set
forth in Section 3 of this Plan. 
 (b)    Each grant will specify an
Option Price per share of Common Stock, which Option Price (except with respect to awards under Section 22 of this Plan) may not be less than the Market Value per Share on the Date of Grant. 

(c)    Each grant will specify whether the Option Price will be payable (i) in cash, by check acceptable to the
Company or by wire transfer of immediately available funds, (ii) by the actual or constructive transfer to the Company of Common Stock owned by the Optionee having a value at the time of exercise equal to the total Option Price,
(iii) subject to any conditions or limitations established by the Committee, by the withholding of Common Stock otherwise issuable upon exercise of an Option Right pursuant to a “net exercise” arrangement (it being understood that,
solely for purposes of determining the number of treasury shares held by the Company, the Common Stock so withheld will not be treated as issued and acquired by the Company upon such exercise), (iv) by a combination of such methods of payment, or
(v) by such other methods as may be approved by the Committee. 
 (d)    To the extent permitted by law, any grant
may provide for deferred payment of the Option Price from the proceeds of sale through a bank or broker on a date satisfactory to the Company of some or all of the Common Stock to which such exercise relates. 

  
 4 

 (e)    Each grant will specify the period or periods of continuous
service by the Optionee with the Company or any Subsidiary, if any, that is necessary before any Option Rights or installments thereof will vest. Option Rights may provide for continued vesting or the earlier vesting of such Option Rights, including
in the event of the retirement, death, disability or termination of employment or service of a Participant or in the event of a Change in Control. 

(f)    Any grant of Option Rights may specify Management Objectives regarding the vesting of such rights. 

(g)    Option Rights granted under this Plan may be (i) options, including Incentive Stock Options, that are intended
to qualify under particular provisions of the Code, (ii) options that are not intended to so qualify, or (iii) combinations of the foregoing. Incentive Stock Options may only be granted to Participants who meet the definition of
“employees” under Section 3401(c) of the Code. 
 (h)    No Option Right will be exercisable more than 10
years from the Date of Grant. The Committee may provide in any Evidence of Award for the automatic exercise of an Option Right upon such terms and conditions as established by the Committee. 

(i)    Option Rights granted under this Plan may not provide for any dividends or dividend equivalents thereon. 

(j)    Each grant of Option Rights will be evidenced by an Evidence of Award. Each Evidence of Award will be subject to
this Plan and will contain such terms and provisions, consistent with this Plan, as the Committee may approve. 

(k)    The Committee may (i) modify, extend or renew outstanding Option Rights (provided that
(A) the rights of a Participant are not substantially impaired without his or her consent and (B) such action does not subject the Option Rights to Section 409A of the Code or otherwise extend the Options Rights beyond their stated
term), and (ii) accept the surrender of outstanding Options Rights and authorize the granting of new Option Rights in substitution therefor. Notwithstanding anything herein to the contrary, an outstanding Option Right may not be modified
to reduce the exercise price thereof nor may a new Option Right at a lower price, any other award under the Plan, or cash be substituted for a surrendered Option Right (other than adjustments or substitutions in accordance with
Section 11), unless such action is approved by the Stockholders of the Company. 

5.    Appreciation Rights. 

(a)    The Committee may, from time to time and upon such terms and conditions as it may determine, authorize the granting
to any Participant of Appreciation Rights. An Appreciation Right will be the right of the Participant to receive from the Company an amount determined by the Committee, which will be expressed as a percentage of the Spread (not exceeding 100%) at
the time of exercise. 
 (b)    Each grant of Appreciation Rights may utilize any or all of the authorizations, and will
be subject to all of the requirements, contained in the following provisions: 
  

	 	(i)	 Each grant may specify that the amount payable on exercise of an Appreciation Right will be paid by the Company
in cash, Common Stock or any combination thereof. 

  

	 	(ii)	 Each grant will specify the period or periods of continuous service by the Participant with the Company or any
Subsidiary, if any, that is necessary before the Appreciation Rights or installments thereof will vest. Appreciation Rights may provide for continued vesting or the earlier vesting of such Appreciation Rights, including in the event of the
retirement, death, disability or termination of employment or service of a Participant or in the event of a Change in Control. 

  

	 	(iii)	 Any grant of Appreciation Rights may specify Management Objectives regarding the vesting of such Appreciation
Rights. 

  
 5 

	 	(iv)	 Appreciation Rights granted under this Plan may not provide for any dividends or dividend equivalents thereon.

  

	 	(v)	 Each grant of Appreciation Rights will be evidenced by an Evidence of Award. Each Evidence of Award will be
subject to this Plan and will contain such terms and provisions, consistent with this Plan, as the Committee may approve. 

(c)    Also, regarding Appreciation Rights: 
  

	 	(i)	 Each grant will specify in respect of each Appreciation Right a Base Price, which (except with respect to
awards under Section 22 of this Plan) may not be less than the Market Value per Share on the Date of Grant; and 

 

	 	(ii)	 No Appreciation Right granted under this Plan may be exercised more than 10 years from the Date of Grant. The
Committee may provide in any Evidence of Award for the automatic exercise of an Appreciation Right upon such terms and conditions as established by the Committee. 

(d)    The Committee may (i) modify, extend or renew outstanding Appreciation Rights (provided that
(A) the rights of a Participant are not substantially impaired without his or her consent and (B) such action does not subject the Appreciation Rights to Section 409A of the Code or otherwise extend the Appreciation Rights beyond
their stated term), and (ii) accept the surrender of outstanding Appreciation Rights and authorize the granting of new Appreciation Rights in substitution therefor. Notwithstanding anything herein to the contrary, an outstanding
Appreciation Right may not be modified to reduce the Base Price thereof nor may a new Appreciation Right at a lower price, any other award under the Plan, or cash be substituted for a surrendered Appreciation Right (other than adjustments or
substitutions in accordance with Section 11), unless such action is approved by the Stockholders of the Company. 

6.    Restricted Stock. The Committee may, from time to time and upon such terms and conditions as it may
determine, authorize the grant or sale of Restricted Stock to Participants. Each such grant or sale may utilize any or all of the authorizations, and will be subject to all of the requirements, contained in the following provisions: 

(a)    Each such grant or sale will constitute an immediate transfer of the ownership of Common Stock to the Participant
in consideration of the performance of services, entitling such Participant to voting, dividend and other ownership rights (subject in particular to Section 6(g) of this Plan), but subject to the
substantial risk of forfeiture and restrictions on transfer hereinafter described. 
 (b)    Each such grant or sale may
be made without additional consideration or in consideration of a payment by such Participant that is less than the Market Value per Share on the Date of Grant. 

(c)    Each such grant or sale will provide that the Restricted Stock covered by such grant or sale will be subject to a
“substantial risk of forfeiture” within the meaning of Section 83 of the Code for a period to be determined by the Committee on the Date of Grant or until achievement of Management Objectives referred to in
Section 6(e) of this Plan. 
 (d)    Each such grant or sale will provide
that during or after the period for which such substantial risk of forfeiture is to continue, the transferability of the Restricted Stock will be prohibited or restricted in the manner and to the extent prescribed by the Committee on the Date of
Grant (which restrictions may include rights of repurchase or first refusal of the Company or provisions subjecting the Restricted Stock to a continuing substantial risk of forfeiture while held by any transferee). 

(e)    Any grant of Restricted Stock may specify Management Objectives regarding the vesting of such Restricted Stock.

 (f)    Notwithstanding anything to the contrary contained in this Plan, Restricted Stock may provide for continued
vesting or the earlier vesting of such Restricted Stock, including in the event of the retirement, death, disability or termination of employment or service of a Participant or in the event of a Change in Control. 

  
 6 

 (g)    Any such grant or sale of Restricted Stock may require that any
and all dividends or other distributions paid thereon during the period of such restrictions be automatically deferred and/or reinvested in additional Restricted Stock, which will be subject to the same restrictions as the underlying award. For the
avoidance of doubt, any such dividends or other distributions on Restricted Stock will be deferred until, and paid contingent upon, the vesting of such Restricted Stock. 

(h)    Each grant or sale of Restricted Stock will be evidenced by an Evidence of Award. Each Evidence of Award will be
subject to this Plan and will contain such terms and provisions, consistent with this Plan, as the Committee may approve. Unless otherwise directed by the Committee, (i) all certificates representing Restricted Stock will be held in custody by
the Company until all restrictions thereon will have lapsed, together with a stock power or powers executed by the Participant in whose name such certificates are registered, endorsed in blank and covering such shares or (ii) all Restricted
Stock will be held at the Company’s transfer agent in book entry form with appropriate restrictions relating to the transfer of such Restricted Stock. 

7.    Restricted Stock Units. The Committee may, from time to time and upon such terms and conditions as it may
determine, authorize the granting or sale of Restricted Stock Units to Participants. Each such grant or sale may utilize any or all of the authorizations, and will be subject to all of the requirements, contained in the following provisions: 

(a)    Each such grant or sale will constitute the agreement by the Company to deliver Common Stock or cash, or a
combination thereof, to the Participant in the future in consideration of the performance of services, but subject to the fulfillment of such conditions (which may include achievement regarding Management Objectives) during the Restriction Period as
the Committee may specify. 
 (b)    Each such grant or sale may be made without additional consideration or in
consideration of a payment by such Participant that is less than the Market Value per Share on the Date of Grant. 

(c)    Notwithstanding anything to the contrary contained in this Plan, Restricted Stock Units may provide for continued
vesting or the earlier lapse or other modification of the Restriction Period, including in the event of the retirement, death, disability or termination or employment of service of a Participant or in the event of a Change in Control. 

(d)    During the Restriction Period, the Participant will have no right to transfer any rights under his or her award and
will have no rights of ownership in the Common Stock deliverable upon payment of the Restricted Stock Units and will have no right to vote them, but the Committee may, at or after the Date of Grant, authorize the payment of dividend equivalents on
such Restricted Stock Units on a deferred and contingent basis, either in cash or in additional Common Stock; provided, however, that dividend equivalents or other distributions on Common Stock underlying Restricted Stock Units shall
be deferred until and paid contingent upon the vesting of such Restricted Stock Units. 
 (e)    Each grant or sale of
Restricted Stock Units will specify the time and manner of payment of the Restricted Stock Units that have been earned. Each grant or sale will specify that the amount payable with respect thereto will be paid by the Company in Common Stock or cash,
or a combination thereof. 
 (f)    Each grant or sale of Restricted Stock Units will be evidenced by an Evidence of
Award. Each Evidence of Award will be subject to this Plan and will contain such terms and provisions, consistent with this Plan, as the Committee may approve. 

8.    Cash Incentive Awards, Performance Shares and Performance Units. The Committee may, from time to time and
upon such terms and conditions as it may determine, authorize the granting of 

  
 7 

 
Cash Incentive Awards, Performance Shares and Performance Units. Each such grant may utilize any or all of the authorizations, and will be subject to all of the requirements, contained in the
following provisions: 
 (a)    Each grant will specify the number or amount of Performance Shares or Performance Units,
or amount payable with respect to a Cash Incentive Award, to which it pertains, which number or amount may be subject to adjustment to reflect changes in compensation or other factors. 

(b)    The Performance Period with respect to each Cash Incentive Award or grant of Performance Shares or Performance
Units will be such period of time as will be determined by the Committee, which may be subject to continued vesting or earlier lapse or other modification, including in the event of the retirement, death, disability or termination of employment or
service of a Participant or in the event of a Change in Control. 
 (c)    Each grant of a Cash Incentive Award,
Performance Shares or Performance Units will specify Management Objectives regarding the earning of the award. 

(d)    Each grant will specify the time and manner of payment of a Cash Incentive Award, Performance Shares or Performance
Units that have been earned. 
 (e)    The Committee may, on the Date of Grant of Performance Shares or Performance
Units, provide for the payment of dividend equivalents to the holder thereof either in cash or in additional Common Stock, which dividend equivalents will be subject to deferral and payment on a contingent basis based on the Participant’s
earning and vesting of the Performance Shares or Performance Units, as applicable, with respect to which such dividend equivalents are paid. 

(f)    Each grant of a Cash Incentive Award, Performance Shares or Performance Units will be evidenced by an Evidence of
Award. Each Evidence of Award will be subject to this Plan and will contain such terms and provisions, consistent with this Plan, as the Committee may approve. 

9.    Other Awards. 

(a)    Subject to applicable law and the applicable limits set forth in
Section 3 of this Plan, the Committee may authorize the grant to any Participant of Common Stock or such other awards that may be denominated or payable in, valued in whole or in part by reference to,
or otherwise based on, or related to, Common Stock or factors that may influence the value of such shares, including, without limitation, convertible or exchangeable debt securities, other rights convertible or exchangeable into Common Stock,
purchase rights for Common Stock, awards with value and payment contingent upon performance of the Company or specified Subsidiaries, affiliates or other business units thereof or any other factors designated by the Committee, and awards valued by
reference to the book value of the Common Stock or the value of securities of, or the performance of specified Subsidiaries or affiliates or other business units of the Company. The Committee will determine the terms and conditions of such awards.
Common Stock delivered pursuant to an award in the nature of a purchase right granted under this Section 9 will be purchased for such consideration, paid for at such time, by such methods, and in such
forms, including, without limitation, Common Stock, other awards, notes or other property, as the Committee determines. 

(b)    Cash awards, as an element of or supplement to any other award granted under this Plan, may also be granted
pursuant to this Section 9. 
 (c)    The Committee may authorize the
grant of Common Stock as a bonus, or may authorize the grant of other awards in lieu of obligations of the Company or a Subsidiary to pay cash or deliver other property under this Plan or under other plans or compensatory arrangements, subject to
such terms as will be determined by the Committee in a manner that complies with Section 409A of the Code. 

(d)    The Committee may, at or after the Date of Grant, authorize the payment of dividends or dividend equivalents on
awards granted under this Section 9 on a deferred and contingent basis, either in cash or in additional Common Stock, based upon the earning and vesting of such awards. 

(e)    Each grant of an award under this Section 9 will be evidenced by an
Evidence of Award. Each such Evidence of Award will be subject to this Plan and will contain such terms and provisions, consistent with this Plan, as the Committee may approve, and will specify the time and terms of delivery of the applicable award.

  
 8 

 (f)    Notwithstanding anything to the contrary contained in this Plan,
awards under this Section 9 may provide for the earning or vesting of, or earlier elimination of restrictions applicable to, such award, including in the event of the retirement, death, disability or
termination of employment or service of a Participant or in the event of a Change in Control. 

10.    Administration of this Plan. 

(a)    This Plan will be administered by the Committee; provided, however, that notwithstanding anything in this Plan to
the contrary, the Board may grant awards under this Plan to non-employee Directors and administer this Plan with respect to such awards. The Committee may from time to time delegate all or any part of its
authority under this Plan to a subcommittee thereof. To the extent of any such delegation, references in this Plan to the Committee will be deemed to be references to such subcommittee. 

(b)    The interpretation and construction by the Committee of any provision of this Plan or of any Evidence of Award (or
related documents) and any determination by the Committee pursuant to any provision of this Plan or of any such agreement, notification or document will be final and conclusive. No member of the Committee shall be liable for any such action or
determination made in good faith. In addition, the Committee is authorized to take any action it determines in its sole discretion to be appropriate subject only to the express limitations contained in this Plan, and no authorization in any Plan
section or other provision of this Plan is intended or may be deemed to constitute a limitation on the authority of the Committee. 

(c)    To the extent permitted by law, the Committee may delegate to one or more of its members, to one or more officers
of the Company, or to one or more agents or advisors, such administrative duties or powers as it may deem advisable, and the Committee, the subcommittee, or any person to whom duties or powers have been delegated as aforesaid, may employ one or more
persons to render advice with respect to any responsibility the Committee, the subcommittee or such person may have under this Plan. The Committee may, by resolution, authorize one or more officers of the Company to do one or both of the following
on the same basis as the Committee: (i) designate employees to be recipients of awards under this Plan; and (ii) determine the size of any such awards; provided, however, that (A) the Committee will not delegate such
responsibilities to any such officer for awards granted to an employee who is an officer (for purposes of Section 16 of the Exchange Act), Director, or more than 10% “beneficial owner” (as such term is defined in Rule 13d-3 promulgated under the Exchange Act) of any class of the Company’s equity securities that is registered pursuant to Section 12 of the Exchange Act, as determined by the Committee in accordance with
Section 16 of the Exchange Act; (B) the resolution providing for such authorization shall set forth the total number of shares of Common Stock such officer(s) may grant; and (C) the officer(s) will report periodically to the Committee
regarding the nature and scope of the awards granted pursuant to the authority delegated. 
 11.    Adjustments.
The Committee shall make or provide for such adjustments in the number of and kind of shares of Common Stock covered by outstanding Option Rights, Appreciation Rights, Restricted Stock, Restricted Stock Units, Performance Shares and Performance
Units granted hereunder and, if applicable, in the number of and kind of shares of Common Stock covered by other awards granted pursuant to Section 9 of this Plan, in the Option Price and Base Price
provided in outstanding Option Rights and Appreciation Rights, respectively, in Cash Incentive Awards, and in other award terms, as the Committee, in its sole discretion, exercised in good faith, determines is equitably required to prevent dilution
or enlargement of the rights of Participants that otherwise would result from (a) any stock dividend, stock split, combination of shares, recapitalization or other change in the capital structure of the Company, (b) any merger,
consolidation, spin-off, split-off, spin-out, split-up, reorganization, partial or
complete liquidation or other distribution of assets, issuance of rights or warrants to purchase securities, or (c) any other corporate transaction or event having an effect similar to any of the foregoing. Moreover, in the event of any such
transaction or event or in the event of a Change in Control, the Committee may provide in substitution for any or all outstanding awards under this Plan such alternative consideration (including cash), if any, as it, in good faith, may determine to
be equitable in the circumstances and shall require in connection therewith the surrender of all awards so replaced in a manner that complies with Section 409A of the Code. In addition, for each Option Right or Appreciation Right with an
Option Price or Base Price, respectively, greater than the consideration offered in connection with any such transaction or event or Change in Control, the Committee may in its discretion elect to cancel such Option Right or Appreciation Right
without any payment to the 

  
 9 

 
person holding such Option Right or Appreciation Right. The Committee shall also make or provide for such adjustments in the number of shares of Common Stock specified in
Section 3 of this Plan as the Committee in its sole discretion, exercised in good faith, determines is appropriate to reflect any transaction or event described in this
Section 11; provided, however, that any such adjustment to the number specified in Section 3(c) of this Plan will be made only if and to the
extent that such adjustment would not cause any Option Right intended to qualify as an Incentive Stock Option to fail to so qualify. 

12.    Change in Control. For purposes of this Plan, except as may be otherwise prescribed by the Committee in an
Evidence of Award made under this Plan, a “Change in Control” will be deemed to have occurred upon the occurrence (after the Effective Date) of any of the following events: 

(a)    Any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act) (a
“Person”) becomes the beneficial owner (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 35% or more of either (i) the then-outstanding shares of Common Stock (the
“Outstanding Company Common Stock”) or (ii) the combined voting power of the then-outstanding voting securities of the Company entitled to vote generally in the election of directors (the “Outstanding Company Voting
Securities”); provided, however, that, for purposes of this definition, the following acquisitions shall not constitute a Change in Control: (A) any acquisition directly from the Company, (B) any acquisition by
the Company, (C) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any Subsidiary or (D) any acquisition pursuant to a transaction that complies with Sections
12(c)(i), (c)(ii) and (c)(iii) below; or 
 (b)    Individuals
who, as of the Effective Date, constitute the Board (the “Incumbent Board”) cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequent
to the Effective Date whose election, or nomination for election by the Stockholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board (either by specific vote or by approval of the proxy statement
of the Company in which such individual is named as a nominee for director, without objection to such nomination) shall be considered as though such individual was a member of the Incumbent Board, but excluding, for this purpose, any such individual
whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person
other than the Board; or 
 (c)    Consummation of a reorganization, merger, statutory share exchange or consolidation
or similar transaction involving the Company or any Subsidiary, a sale or other disposition of all or substantially all of the assets of the Company, or the acquisition of assets or securities of another entity by the Company or any Subsidiary
(each, a “Business Combination”), in each case unless, following such Business Combination, (i) all or substantially all of the individuals and entities that were the beneficial owners of the Outstanding Company Common Stock and the
Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50% of the then-outstanding shares of common stock (or, for a
non-corporate entity, equivalent securities) and the combined voting power of the then-outstanding voting securities entitled to vote generally in the election of directors (or, for a non-corporate entity, equivalent governing body), as the case may be, of the entity resulting from such Business Combination (including, without limitation, an entity that, as a result of such transaction, owns the
Company or all or substantially all of the Company’s assets either directly or through one or more subsidiaries) in substantially the same proportions as their ownership immediately prior to such Business Combination of the Outstanding Company
Common Stock and the Outstanding Company Voting Securities, as the case may be, (ii) no Person (excluding any entity resulting from such Business Combination or any employee benefit plan (or related trust) of the Company or such entity
resulting from such Business Combination) beneficially owns, directly or indirectly, 35% or more of, respectively, the then-outstanding shares of common stock (or, for a non-corporate entity, equivalent
securities) of the entity resulting from such Business Combination or the combined voting power of the then-outstanding voting securities of such entity, except to the extent that such ownership existed prior to the Business Combination, and
(iii) at least a majority of the members of the board of directors (or, for a non-corporate entity, equivalent governing body) of the entity resulting from such Business Combination were members of the
Incumbent Board at the time of the execution of the initial agreement or of the action of the Board providing for such Business Combination; or 

(d)    Approval by the Stockholders of a complete liquidation or dissolution of the Company. 

  
 10 

 13.    Detrimental Activity and Recapture Provisions. Any
Evidence of Award may reference a clawback policy of the Company or provide for the cancellation or forfeiture of an award or the forfeiture and repayment to the Company of any gain related to an award, or other provisions intended to have a similar
effect, upon such terms and conditions as may be determined by the Committee from time to time, if a Participant, either (a) during employment or other service with the Company or a Subsidiary, or (b) within a specified period after
termination of such employment or service, engages in any detrimental activity, as described in the applicable Evidence of Award or such clawback policy. In addition, notwithstanding anything in this Plan to the contrary, any Evidence of Award or
such clawback policy may also provide for the cancellation or forfeiture of an award or the forfeiture and repayment to the Company of any Common Stock issued under and/or any other benefit related to an award, or other provisions intended to have a
similar effect, including upon such terms and conditions as may be required by the Committee or under Section 10D of the Exchange Act and any applicable rules or regulations promulgated by the Securities and Exchange Commission or any national
securities exchange or national securities association on which the Common Stock may be traded. 
 14.    Non-U.S. Participants. In order to facilitate the making of any grant or combination of grants under this Plan, the Committee may provide for such special terms for awards to Participants who are foreign
nationals or who are employed by the Company or any Subsidiary outside of the United States of America or who provide services to the Company or any Subsidiary under an agreement with a foreign nation or agency, as the Committee may consider
necessary or appropriate to accommodate differences in local law, tax policy or custom. Moreover, the Committee may approve such supplements to or amendments, restatements or alternative versions of this Plan (including sub-plans) (to be considered part of this Plan) as it may consider necessary or appropriate for such purposes, without thereby affecting the terms of this Plan as in effect for any other purpose, and the secretary
or other appropriate officer of the Company may certify any such document as having been approved and adopted in the same manner as this Plan. No such special terms, supplements, amendments or restatements, however, will include any provisions that
are inconsistent with the terms of this Plan as then in effect unless this Plan could have been amended to eliminate such inconsistency without further approval by the Stockholders. 

15.    Transferability. 

(a)    Except as otherwise determined by the Committee, and subject to compliance with
Section 17(b) of this Plan and Section 409A of the Code, no Option Right, Appreciation Right, Restricted Share, Restricted Share Unit, Performance Share, Performance Unit, Cash Incentive Award,
award contemplated by Section 9 of this Plan or dividend equivalents paid with respect to awards made under this Plan will be transferable by the Participant except by will or the laws of descent and
distribution. In no event will any such award granted under this Plan be transferred for value. Where transfer is permitted, references to “Participant” shall be construed, as the Committee deems appropriate, to include any permitted
transferee to whom such award is transferred. Except as otherwise determined by the Committee, Option Rights and Appreciation Rights will be exercisable during the Participant’s lifetime only by him or her or, in the event of the
Participant’s legal incapacity to do so, by his or her guardian or legal representative acting on behalf of the Participant in a fiduciary capacity under state law or court supervision. 

(b)    The Committee may specify on the Date of Grant that part or all of the Common Stock that is (i) to be issued
or transferred by the Company upon the exercise of Option Rights or Appreciation Rights, upon the termination of the Restriction Period applicable to Restricted Stock Units or upon payment under any grant of Performance Shares or Performance Units
or (ii) no longer subject to the substantial risk of forfeiture and restrictions on transfer referred to in Section 6 of this Plan, will be subject to further restrictions on transfer, including
minimum holding periods. 
 16.    Withholding Taxes. To the extent that the Company is required to withhold
federal, state, local or foreign taxes or other amounts in connection with any payment made or benefit realized by a Participant or other person under this Plan, and the amounts available to the Company for such withholding are insufficient, it will
be a condition to the receipt of such payment or the realization of such benefit that the Participant or such other person make arrangements satisfactory to the Company for payment of the balance of such taxes or other amounts required to be
withheld, which arrangements (in the discretion of the Committee) may include relinquishment of a portion of such benefit. If a Participant’s benefit is to be received in the form of Common Stock, and such Participant fails to make arrangements
for the payment of taxes or other amounts, then, unless otherwise determined by the Committee, the Company will withhold Common Stock having a 

  
 11 

 
value equal to the amount required to be withheld. Notwithstanding the foregoing, when a Participant is required to pay the Company an amount required to be withheld under applicable income,
employment, tax or other laws, to the extent permitted by the Committee in its sole discretion, the Participant may elect to satisfy the obligation, in whole or in part, by (i) having withheld, from the Common Stock required to be delivered to
the Participant, Common Stock having a value up to the maximum individual tax rate in each relevant jurisdiction applicable to the Participant at such time of withholding, so long as the withholdings do not result in adverse accounting consequences
to the Company (as determined by the Company in its sole discretion) or (ii) delivering to the Company other shares of Common Stock held by such Participant. The Common Stock used for tax or other withholding will be valued at an amount equal
to the fair market value of such Common Stock on the date the benefit is to be included in Participant’s income. Participants will also make such arrangements as the Company may require for the payment of any withholding tax or other obligation
that may arise in connection with the disposition of Common Stock acquired upon the exercise of Option Rights. 

17.    Compliance with Section 409A of the Code. 

(a)    To the extent applicable, it is intended that this Plan and any grants made hereunder comply with the provisions of
Section 409A of the Code, so that the income inclusion provisions of Section 409A(a)(1) of the Code do not apply to the Participants. This Plan and any grants made hereunder will be administered in a manner consistent with this intent. Any
reference in this Plan to Section 409A of the Code will also include any regulations or any other formal guidance promulgated with respect to such section by the U.S. Department of the Treasury or the Internal Revenue Service. 

(b)    Neither a Participant nor any of a Participant’s creditors or beneficiaries will have the right to subject any
deferred compensation (within the meaning of Section 409A of the Code) payable under this Plan and grants hereunder to any anticipation, alienation, sale, transfer, assignment, pledge, encumbrance, attachment or garnishment. Except as permitted
under Section 409A of the Code, any deferred compensation (within the meaning of Section 409A of the Code) payable to a Participant or for a Participant’s benefit under this Plan and grants hereunder may not be reduced by, or offset
against, any amount owed by a Participant to the Company or any of its Subsidiaries. 
 (c)    If, at the time of a
Participant’s separation from service (within the meaning of Section 409A of the Code), (i) the Participant will be a specified employee (within the meaning of Section 409A of the Code and using the identification methodology
selected by the Company from time to time) and (ii) the Company makes a good faith determination that an amount payable hereunder constitutes deferred compensation (within the meaning of Section 409A of the Code) the payment of which is
required to be delayed pursuant to the six-month delay rule set forth in Section 409A of the Code in order to avoid taxes or penalties under Section 409A of the Code, then the Company will not pay
such amount on the otherwise scheduled payment date but will instead pay it, without interest, on the tenth business day of the seventh month after such separation from service. 

(d)    Solely with respect to any award that constitutes nonqualified deferred compensation subject to Section 409A
of the Code and that is payable on account of a Change in Control (including any installments or stream of payments that are accelerated on account of a Change in Control), a Change in Control shall occur only if such event also constitutes a
“change in the ownership,” “change in effective control,” and/or a “change in the ownership of a substantial portion of assets” of the Company as those terms are defined under Treasury Regulation §1.409A-3(i)(5), but only to the extent necessary to establish a time and form of payment that complies with Section 409A of the Code, without altering the definition of Change in Control for any purpose
in respect of such award. 
 (e)    Notwithstanding any provision of this Plan and grants hereunder to the contrary, in
light of the uncertainty with respect to the proper application of Section 409A of the Code, the Company reserves the right to make amendments to this Plan and grants hereunder as the Company deems necessary or desirable to avoid the imposition
of taxes or penalties under Section 409A of the Code. In any case, a Participant will be solely responsible and liable for the satisfaction of all taxes and penalties that may be imposed on a Participant or for a Participant’s account in
connection with this Plan and grants hereunder (including any taxes and penalties under Section 409A of the Code), and neither the Company nor any of its affiliates will have any obligation to indemnify or otherwise hold a Participant harmless
from any or all of such taxes or penalties. 

  
 12 

 18.    Amendments. 

(a)    The Board may at any time and from time to time amend this Plan in whole or in part; provided,
however, that if an amendment to this Plan, for purposes of applicable stock exchange rules and except as permitted under Section 11 of this Plan, (i) would materially increase the benefits
accruing to Participants under this Plan, (ii) would materially increase the number of securities which may be issued under this Plan, (iii) would materially modify the requirements for participation in this Plan, or (iv) must
otherwise be approved by the Stockholders in order to comply with applicable law or the rules of the Nasdaq Stock Market or, if the Common Stock is not traded on the Nasdaq Stock Market, the principal national securities exchange upon which the
Common Stock is traded or quoted, all as determined by the Board, then, such amendment will be subject to Stockholder approval and will not be effective unless and until such approval has been obtained. 

(b)    If permitted by Section 409A of the Code, but subject to the paragraph that follows, including in the case of
termination of employment or service, or in the case of unforeseeable emergency or other circumstances or in the event of a Change in Control, to the extent a Participant holds an Option Right or Appreciation Right not immediately exercisable in
full, or any Restricted Stock as to which the substantial risk of forfeiture or the prohibition or restriction on transfer has not lapsed, or any Restricted Stock Units as to which the Restriction Period has not been completed, or any Cash Incentive
Awards, Performance Shares or Performance Units which have not been fully earned, or any dividend equivalents or other awards made pursuant to Section 9 of this Plan subject to any vesting schedule or
transfer restriction, or who holds Common Stock subject to any transfer restriction imposed pursuant to Section 15(b) of this Plan, the Committee may, in its sole discretion, provide for continued
vesting or accelerate the time at which such Option Right, Appreciation Right or other award may vest or be exercised or the time at which such substantial risk of forfeiture or prohibition or restriction on transfer will lapse or the time when such
Restriction Period will end or the time at which such Cash Incentive Awards, Performance Shares or Performance Units will be deemed to have been earned or the time when such transfer restriction will terminate or may waive any other limitation or
requirement under any such award. 
 (c)    The Committee may amend the terms of any award theretofore granted under
this Plan prospectively or retroactively. Except for adjustments made pursuant to Section 11 of this Plan, no such amendment will materially impair the rights of any Participant without his or her
consent. The Board may, in its discretion, terminate this Plan at any time. Termination of this Plan will not affect the rights of Participants or their successors under any awards outstanding hereunder and not exercised in full on the date of
termination. 
 19.    Governing Law. This Plan and all grants and awards and actions taken hereunder will be
governed by and construed in accordance with the internal substantive laws of the State of Delaware. 

20.    Effective Date/Termination. This Plan will be effective as of the Effective Date. No grant will be made
under this Plan on or after the tenth anniversary of the Effective Date, but all grants made prior to such date will continue in effect thereafter subject to the terms thereof and of this Plan. 

21.    Miscellaneous Provisions. 

(a)    The Company will not be required to issue any fractional Common Stock pursuant to this Plan. The Committee may
provide for the elimination of fractions or for the settlement of fractions in cash. 
 (b)    This Plan will not confer
upon any Participant any right with respect to continuance of employment or other service with the Company or any Subsidiary, nor will it interfere in any way with any right the Company or any Subsidiary would otherwise have to terminate such
Participant’s employment or other service at any time. 
 (c)    Except with respect to
Section 21(e) of this Plan, to the extent that any provision of this Plan would prevent any Option Right that was intended to qualify as an Incentive Stock Option from qualifying as such, that provision
will be null and void with respect to such Option Right. Such provision, however, will remain in effect for other Option Rights and there will be no further effect on any provision of this Plan. 

  
 13 

 (d)    No award under this Plan may be exercised by the holder thereof
if such exercise, and the receipt of cash or shares thereunder, would be, in the opinion of counsel selected by the Company, contrary to law or the regulations of any duly constituted authority having jurisdiction over this Plan. 

(e)    Absence on leave approved by a duly constituted officer of the Company or any of its Subsidiaries will not be
considered interruption or termination of service of any employee for any purposes of this Plan or awards granted hereunder. 

(f)    No Participant will have any rights as a Stockholder with respect to any Common Stock subject to awards granted to
him or her under this Plan prior to the date as of which he or she is actually recorded as the holder of such Common Stock upon the share records of the Company. 

(g)    The Committee may condition the grant of any award or combination of awards authorized under this Plan on the
surrender or deferral by the Participant of his or her right to receive a cash bonus or other compensation otherwise payable by the Company or a Subsidiary to the Participant. 

(h)    Except with respect to Option Rights and Appreciation Rights, the Committee may permit Participants to elect to
defer the issuance of Common Stock under this Plan pursuant to such rules, procedures or programs as it may establish for purposes of this Plan and which are intended to comply with the requirements of Section 409A of the Code. The Committee
also may provide that deferred issuances and settlements include the crediting of dividend equivalents or interest on the deferral amounts. 

(i)    If any provision of this Plan is or becomes invalid or unenforceable in any jurisdiction, or would disqualify this
Plan or any award under any law deemed applicable by the Committee, such provision will be construed or deemed amended or limited in scope to conform to applicable laws or, in the discretion of the Committee, it will be stricken and the remainder of
this Plan will remain in full force and effect. Notwithstanding anything in this Plan or an Evidence of Award to the contrary, nothing in this Plan or in an Evidence of Award prevents a Participant from providing, without prior notice to the
Company, information to governmental authorities regarding possible legal violations or otherwise testifying or participating in any investigation or proceeding by any governmental authorities regarding possible legal violations, and for purpose of
clarity a Participant is not prohibited from providing information voluntarily to the Securities and Exchange Commission pursuant to Section 21F of the Exchange Act. 

22.    Share-Based Awards in Substitution for Awards Granted by Another Company. Notwithstanding anything in this
Plan to the contrary: 
 (a)    Awards may be granted under this Plan in substitution for or in conversion of, or in
connection with an assumption of, stock options, stock appreciation rights, restricted stock, restricted stock units or other share or share-based awards held by awardees of an entity engaging in a corporate acquisition or merger transaction with
the Company or any Subsidiary. Any conversion, substitution or assumption will be effective as of the close of the merger or acquisition, and, to the extent applicable, will be conducted in a manner that complies with Section 409A of the Code.
The awards so granted may reflect the original terms of the awards being assumed or substituted or converted for and need not comply with other specific terms of this Plan, and may account for Common Stock substituted for the securities covered by
the original awards and the number of shares subject to the original awards, as well as any exercise or purchase prices applicable to the original awards, adjusted to account for differences in stock prices in connection with the transaction. 

(b)    In the event that a company acquired by the Company or any Subsidiary or with which the Company or any Subsidiary
merges has shares available under a pre-existing plan previously approved by stockholders and not adopted in contemplation of such acquisition or merger, the shares available for grant pursuant to the terms of
such plan (as adjusted, to the extent appropriate, to reflect such acquisition or merger) may be used for awards made after such acquisition or merger under this Plan; provided, however, that awards using such available shares may not
be made after the date awards or grants could have been made under the terms of the pre-existing plan absent the acquisition or merger, and may only be made to individuals who were not employees or directors
of the Company or any Subsidiary prior to such acquisition or merger. 
 (c)    Any Common Stock that is issued or
transferred by, or that are subject to any awards that are granted by, or become obligations of, the Company under Sections 22(a) or 22(b) of this Plan will not reduce the Common
Stock available for issuance or transfer under this Plan or otherwise count against the 

  
 14 

 
limits contained in Section 3 of this Plan. In addition, no Common Stock subject to an award that is granted by, or becomes an obligation of, the
Company under Sections 22(a) or 22(b) of this Plan, will be added to the aggregate limit contained in Section 3(a)(i) of this Plan. 

  
 15 

 Appendix I 

Country-Specific Provisions 
 Terms
and Conditions 
 This Appendix includes additional terms and conditions that govern the awards granted under the Plan if a
Participant resides in one of the countries listed below. Certain capitalized terms used but not defined in this Appendix have the meanings set forth in the Plan and/or the main body of the applicable Evidence of Award. 

Notifications 
 The information in this Appendix is
based on laws in effect in the respective countries as of December 2020. Such laws are often complex and change frequently. As a result, the Company strongly recommends that Participant not rely on the information in this Appendix as the only source
of information relating to the consequences of Participant’s participation in the Plan. 
 In addition, the information contained herein is general in
nature and may not apply to Participant’s particular situation and the Company is not in a position to assure Participant of any particular result. Accordingly, Participant is advised to seek appropriate professional advice as to how the
relevant laws of Participant’s country may apply to his or her situation. 
 Finally, if Participant is a citizen or resident of a country other than
the one in which Participant is working or transfers to another country after the grant of an award to Participant, or is considered a resident of another country for local law purposes, the information contained herein may not be applicable to
Participant in the same manner. In addition, the Company shall, in its discretion, determine to what extent the terms and conditions contained herein shall apply to a Participant under these circumstances. 

Australia 
 Except to the extent that an award is granted
on the basis that the award will be settled only in cash, no Option Right, Appreciation Right, Restricted Share, Restricted Share Unit, Performance Share, Performance Unit, or award contemplated by Section 9 of this Plan or Common Stock may
be granted, issued or sold to Participants resident in Australia unless that Participant is eligible to receive the award without a disclosure document for the purposes of the Corporations Act 2001 (Cth) (the “Corporations Act”),
including under an applicable exemption set out in section 708 of the Corporations Act (“Eligible Australian Participant”). 
 Any Eligible
Australian Participant who receives an Option Right, Appreciation Right, Restricted Share, Restricted Share Unit, Performance Share, Performance Unit, award contemplated by Section 9 of this Plan (excluding any award settled in cash) or
Common Stock (“Securities”) shall not sell, transfer or otherwise dispose of the Securities, nor any Common Stock issued or transferred pursuant to such Securities, in Australia within 12 months of their grant, issue or sale without
disclosure under the Corporations Act, unless an exemption applies. 
 Tax Information 

This Plan is a plan to which Subdivision 83A-C of the Tax Act applies (subject to the conditions in the Income Tax Assessment Act 1997 (Cth)).

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00318-of-00352.parquet"}]]